Novel protein kinase C phosphorylated kinase inhibitor-matrine suppresses replication of hepatitis B virus via modulating the mitogen-activated protein kinase signal. Issue 2 (1st February 2022)
- Record Type:
- Journal Article
- Title:
- Novel protein kinase C phosphorylated kinase inhibitor-matrine suppresses replication of hepatitis B virus via modulating the mitogen-activated protein kinase signal. Issue 2 (1st February 2022)
- Main Title:
- Novel protein kinase C phosphorylated kinase inhibitor-matrine suppresses replication of hepatitis B virus via modulating the mitogen-activated protein kinase signal
- Authors:
- Zhou, Shen
Li, Yuan
Gao, Jing
Wang, Yanyan
Ma, Xinping
Ding, Hui
Li, Xiuling
Sun, Suofeng - Abstract:
- ABSTRACT: HBV (hepatitis B virus) infection still threatens human health. Therefore, it is essential to find new effective anti-HBV compounds. Here, we identified matrine as a novel inhibitor of PKC (protein kinase C) phosphorylated kinase by screening a natural compound library. After HepG2.215 cells were treated with matrine, we carried out a phosphorylated proteomics sequence study and analyzed the prediction of related kinase expression level. In the case of HBV infection, it was found that PKC kinase mediates the activation of mitogen-activated protein kinase (MAPK) signaling pathway known as son of sevenless (SOS) activation. It was also found that PKC kinase inhibits the expression of C-X-C Motif Chemokine Ligand 8 (CXCL8) by inhibiting the activity of activating transcription factor 2/ cAMP response element binding protein (ATF2/CREB), and this effect is independent of its activated MAPK signaling pathway. Finally, Western blot was used to detect the expression of MAPK, ATF2, CREB3 phosphorylation and nonphosphorylation in matrine-treated cells and PKC-treated cells. PKC phosphorylated kinase inhibitor-matrine suppresses the replication of HBV via modulating the MAPK/ATF2 signal. Matrine is a good clinical drug to enhance the autoimmunity in the adjuvant treatment of chronic HBV infection. Graphical Abstract: uf0001
- Is Part Of:
- Bioengineered. Volume 13:Issue 2(2022)
- Journal:
- Bioengineered
- Issue:
- Volume 13:Issue 2(2022)
- Issue Display:
- Volume 13, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 13
- Issue:
- 2
- Issue Sort Value:
- 2022-0013-0002-0000
- Page Start:
- 2851
- Page End:
- 2865
- Publication Date:
- 2022-02-01
- Subjects:
- Matrine -- HBV -- PKC -- phosphoproteome analysis -- MAPK signaling pathway
Biomedical engineering -- Periodicals
Biotechnology -- Periodicals
Microbiology -- Periodicals
660.6 - Journal URLs:
- http://www.tandfonline.com/toc/kbie20/current ↗
http://www.landesbioscience.com/journals/bioe/ ↗
http://www.tandfonline.com/ ↗ - DOI:
- 10.1080/21655979.2021.2024957 ↗
- Languages:
- English
- ISSNs:
- 2165-5987
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20364.xml